Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Metabolic syndrome linked to increased risk of primary liver cancers

Metabolic syndrome linked to increased risk of primary liver cancers

Series of articles explore recent evidence-based vascular medicine

Series of articles explore recent evidence-based vascular medicine

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Regular physical activity may reduce rates of cognitive impairment in older adults

Regular physical activity may reduce rates of cognitive impairment in older adults

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

IQWiG finds no differences between two treatment strategies for type 2 diabetes

IQWiG finds no differences between two treatment strategies for type 2 diabetes

Poisonous shrub extract may act as natural painkiller

Poisonous shrub extract may act as natural painkiller

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Exenatide tQT clinical trial meets pre-specified primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

Very low calorie diet can reverse type 2 diabetes: Study

Very low calorie diet can reverse type 2 diabetes: Study

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Diabetic patients can benefit from basal insulin analogs

Diabetic patients can benefit from basal insulin analogs

Surgical lung injury prediction model can help identify patients at high risk of ALI

Surgical lung injury prediction model can help identify patients at high risk of ALI

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

New-onset diabetes risk increases with intensive-dose statin therapy

New-onset diabetes risk increases with intensive-dose statin therapy

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.